SERA Earnings

SERA reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 16.00K against an estimate of 100.00K, resulting in a -84% surprise. The EPS was -0.16, surpassing the expected -0.19 by 15.79% . The stock experienced a 0.34% price change on the earnings day and a 8.47% change over the next five days, reflecting market reactions to the results.

Following SERA's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by 0.34% on the day of the release. Over the subsequent five days, it saw a 8.47% change. Historically, SERA's stock price tends to shift by an average of +6.54% in the 10 days leading up to earnings and -6.61% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SERA’s annual revenue to reach 40.00K, while the EPS is projected at -0.20. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Downward by -50% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SERA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Downward by -50% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SERA's stock price typically moves by +6.54% in the 10 days before its earnings and -6.61% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.20 and revenue of 40.00K.

The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.